Introduction
The p53 gene encodes a transcription factor activated by oncogenic and proliferative signals and DNA damage that initiates one of four physiological pathways: apoptosis, cell-cycle arrest, DNA repair and senescence (Ko and Prives, 1996; Vogelstein et al., 2000) . Because p53 regulates each of the aforementioned pathways, it sits at the nexus of a complex network of signals that regulate proliferation and thus cancer development. However, in vivo, the specific effect that each of these individual pathways have on tumor suppression is unknown.
Analysis of human tumors has led to the identification of a rare point mutation in p53 that results in an arginineto-proline substitution at amino acid 175 Rowan et al., 1996) . The p53R175P protein retains the ability to induce cell-cycle arrest by transcriptional activation of p21, but is defective in initiating p53-dependent apoptotic programs Rowan et al., 1996) . This rare naturally occurring p53 allele encodes a separation-of-function mutant p53 protein that can be exploited experimentally to understand the effect of different p53 functions on tumor suppression in vivo. A knock-in mouse model, carrying a G-to-C substitution at position 515 (p53 515C ), mimics precisely the mutation found in humans by altering arginine to proline at the corresponding amino acid 172 in the mouse (Liu et al., 2004) . Homozygous mutant p53 515C/515C embryos and thymocytes lack p53-dependent apoptosis after ionizing radiation (Liu et al., 2004) . Moreover, expression arrays of irradiated mouse embryonic fibroblasts (MEFs) indicate that p53
515C/515C
MEFs do not induce p53-dependent apoptotic targets (Barboza et al., 2006) . p53 515C/515C mice show a significant delay in tumor formation when compared with p53 -/-mice, through p53R172P-dependent transactivation of the cell-cycle inhibitor p21 (Liu et al., 2004; Barboza et al., 2006) . These studies indicate that both cell-cycle arrest and apoptotic programs contribute to suppression of spontaneous tumor development Liu et al., 2004; Barboza et al., 2006) .
As indicated above, p53R172P transactivates the cellcycle inhibitor, p21 Liu et al., 2004; Barboza et al., 2006) . Upon activation, p21 disrupts cell-cycle progression by binding to and inhibiting both cyclin-dependent kinase-cyclin complexes (Gu et al., 1993; Harper et al., 1993; Serrano et al., 1993; Xiong et al., 1993; el-Deiry et al., 1993) and proliferating cell nuclear antigen (Waga et al., 1994) . In addition, p21 is a potent activator of cell senescence (Noda et al., 1994; Kulju and Lehman, 1995; Tahara et al., 1995; Brown et al., 1997) . Owing to the antiproliferative effects of p53 and p21, tumors should inactivate either of these genes to overcome the growth constraints imposed by them.
In human tumors, p53 mutations are common but mutations in p21 are rare (Shiohara et al., 1994) , suggesting that the selective pressure is predominantly directed toward ablating the pleiotropic effects of p53 rather than uniquely the p21-dependent cell-cycle arrest/ senescence activity. Not surprisingly, most mutations and/or deletions of the p53 allele encountered in human cancer result in loss of all p53 functions.
The Em-myc B-cell lymphoma model, in which c-myc is expressed under the control of the immunoglobulin heavy chain enhancer (Adams et al., 1985) , has been used extensively to study alterations in the p53 pathway. Em-myc transgenic mice overexpress c-myc in B cells and succumb to B-cell lymphomas with a mean survival of 4-6 months. The overexpression of c-myc results in increased levels of the p19
Arf tumor suppressor, which in turn, inhibits the function of murine double minute 2, an E3 ubiquitin ligase that degrades p53, thus leading to the stabilization of p53 (Sherr et al., 2005) . This sequence of events places selective pressure on the cancer cell to mutate or inactivate the p53 pathway.
The importance of p53-dependent apoptosis in Em-myc B-cell lymphomas is well established (Eischen et al., 1999 (Eischen et al., , 2001 Schmitt et al., 2002a) . However, the effect of p53-dependent cell-cycle arrest or senescence remains controversial. The progression of lymphomas elicited by c-myc overexpression has been generally attributed to impedance of apoptosis (Schmitt et al., 2002a) . On the other hand, other studies have shown that the increased lymphomagenesis observed in Em-myc:: p53 þ /-mice is the result of increased proliferation and not decreased apoptosis (Hsu et al., 1995) . The role of proliferation in Em-myc lymphomas was further examined in Em-myc crosses with Rb heterozygous mice. Retinoblastoma protein binds E2F and inhibits cell-cycle proliferation (Bandara and La Thangue, 1991; Beenken et al., 1991) . Em-myc::Rb þ /-mice showed increased incidence of lymphomagenesis when compared with Em-myc mice, further supporting the importance of proliferation in Em-myc-induced B-cell lymphomas (Schmitt et al., 1999) . In addition, p53-dependent senescence was shown to delay tumor progression in a reconstituted model upon cyclophosphamide treatment or telomere shortening in B-cell leukemia/lymphoma 2-expressing Em-myc lymphoma cells (Schmitt et al., 2002b; Feldser and Greider, 2007) . It is likely that all three of these p53 activities, that is, apoptosis, senescence and cell-cycle arrest, affect lymphomagenesis to varying degrees.
To directly address the interplay between Em-mycand p53-dependent apoptosis and senescence/cell-cycle arrest functions in vivo, we crossed transgenic mice expressing Em-myc with mice carrying the p53 515C allele. This has allowed us to definitively determine whether the p53 515C allele behaves as a p53-null allele (provides no delay in lymphomas) or whether this hypomorphic allele does in fact affect B-cell lymphomagenesis (delays lymphomagenesis compared with the null allele). In this study we show that both Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice survive longer than Em-myc:: p53 , as well as Em-myc::p53 515C/ þ mice have significantly higher levels of senescence-associated b-galactosidase (SA b-gal) activity than lymphomas from Em-myc:: p53 þ /-mice. These data show that the senescence function of p53 also contributes significantly in delaying B-cell lymphomagenesis in vivo.
Results
The apoptosis-defective p53 515C allele delays tumorigenesis We have previously generated mice containing the p53 515C allele that encodes a hypomorphic p53R172P protein that is able to transactivate p21, but not p53-dependent apoptotic genes (Liu et al., 2004; Barboza et al., 2006) . p21 is a cell-cycle inhibitor and effector of senescence (Gu et al., 1993; Harper et al., 1993; Serrano et al., 1993; Xiong et al., 1993; el-Deiry et al., 1993; Noda et al., 1994) . To determine whether the cellular senescence function of p53 influences the development of Em-myc-induced B-cell lymphomas, we crossed Em-myc transgenic mice with p53 515C/ þ mice to generate Em-myc::p53 515C/ þ mice. Em-myc:: p53 515C/ þ male and female mice were infertile because of the fact that they were already unhealthy at breeding age. Therefore, we generated Em-myc::p53 515C/515C mice through embryo rederivation using 3-week-old Em-myc:: p53 515C/ þ females, in which follicular development was hormonally induced to control the timing of ovulation. Females were then mated with either p53 515C/ þ or p53 515C/515C male mice. Oviducts were harvested from donor females the next morning and embryos at the one-cell stage were collected and implanted in pseudopregnant recipients. The resulting Em-myc::p53 515C/515C and Em-myc:: p53 515C/ þ mice, similar to the Em-myc::p53 þ / þ and Em-myc::p53 þ /-mice, developed B-cell lymphomas throughout all lymphatic tissues and bone marrow, as determined by immunostaining using the B-cell marker, B-220 (data not shown). Importantly, Em-myc::p53
and Em-myc::p53 515C/ þ mice survived significantly longer than Em-myc::p53 þ /-mice ( Figure 1 ). The median survival of Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice was 62 and 69 days, respectively, and both survived significantly longer than Em-myc::p53 þ /-(35 days, Po0.0001 and Po0.0001, respectively). There was no significant difference between the survival of the Em-myc::p53 515C/ þ and Em-myc::p53 515C/515C mice (P ¼ 0.073). Although the p53
515C
allele rendered a significant delay in lymphomagenesis, this hypomorphic allele is not as efficacious a tumor suppressor as the wild-type p53 allele, given that Em-myc::p53 þ / þ mice survive significantly longer than Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice, with a median survival of 138 days (Po0.0001; Figure 1 ).
Selection pressure on the p53
515C allele in Em-myc-driven lymphomagenesis To examine the molecular events taking place at the p53 locus during lymphomagenesis, we analyzed lymphomas p53-dependent senescence delays lymphomagenesis SM Post et al from the Em-myc mice with different p53 alleles. Lymphomas that developed in Em-myc::p53 þ / þ mice retained a wild-type p53 allele >70% of the time and rarely underwent biallelic deletions of p53 loci (Eischen et al., 1999) . All the lymphomas (100%) arising in Em-myc::p53 þ / þ (n ¼ 8) and Em-myc::p53 515C/515C (n ¼ 6) mice that we examined retained a p53 allele. In contrast, all lymphomas from the Em-myc::p53 þ /-mice (n ¼ 3) lost the wild-type p53 allele as previously published ( Figure 2a ; Eischen et al., 1999; Schmitt et al., 1999) . As with the lymphomas from the Em-myc::p53 þ / þ and Em-myc::p53 515C/515C backgrounds, lymphomas isolated from the Em-myc::p53 515C/ þ mice retained at least one p53 allele (Figure 2a ). We sequenced the PCR products to distinguish between p53 allele(s) retained in the Em-myc::p53 515C/ þ lymphomas. The p53 alleles are easily distinguishable by the fact that the wild-type p53 allele has a G-nucleotide at position 515, whereas the p53 515C allele has a C-nucleotide at this position (Liu et al., 2004) . In all, 39% (7/18) of Em-myc::p53 515C/ þ lymphomas lost the wild-type p53 allele, but 44% (8/18) remained heterozygous for both wild-type p53 and p53 515C alleles. Moreover, 17% (3/18) of Em-myc:: p53 515C/ þ lymphomas lost the p53 515C allele (Figure 2b ), indicating the presence of selective pressure to disrupt the function of p53R172P. Sequence analysis of the full-length p53 transcripts revealed no additional mutations in either the wild-type p53 or p53 515C allele in 13 Em-myc::p53 515C/ þ lymphomas examined, whereas two of eight (25%) control Em-myc::p53 þ / þ lymphomas had mutated p53 (data not shown), in agreement with previous reports (Eischen et al., 1999) . Importantly, there was no statistical difference in the survival of Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice that developed lymphomas that lost the wild-type p53 allele when compared with those that lost the p53 515C allele, or those that retained both alleles (Figure 2c ), again emphasizing the protective function of the p53 515C allele in delaying lymphomagenesis.
p53 is expressed in most Em-myc::p53
and Em-myc::p53 515C/ þ lymphomas The Em-myc mice used in this study overexpress c-myc in B cells that result in wild-type p53 stabilization. As a result, a disruption of p53-dependent pathways occurs at high frequency in Em-myc-driven lymphomas (Eischen et al., 1999 (Eischen et al., , 2001 Schmitt et al., 1999) . Analysis of control Em-myc::p53 þ / þ lymphomas showed a The p53 515C allele undergoes similar selection pressure as the wild-type p53 allele in Em-myc-dependent lymphomas. (a) PCR analysis of the p53 locus using primers designed to amplify exons 5-7. The p53 pseudogene (C) serves as internal loading control for the PCR reaction. The asterisk denoted the p53 515C mutation in exon 5. (b) Loss of heterozygosity varies at the p53 locus in Em-myc::p53 515C/ þ lymphomas. The p53 gene was sequenced in 18 lymphomas of Em-myc::p53 515C/ þ mice to determine which allele(s) were retained. B, both alleles retained; P, p53 515C allele retained; Wt, wild-type p53 allele retained. (c) Kaplan-Meier curves indicating survival of Em-myc::p53 515C/515C and Em-myc:: p53 515C/ þ mice that retain the wild-type p53 allele (Wt), the p53 515C allele (P) or both (B). (Figure 3b ; Eischen et al., 1999) . Conversely, Em-myc::p53 þ /-lymphomas, which have lost the remaining wild-type p53 allele, express no p53 as expected (Figures 3a and b ; Eischen et al., 1999) . Analysis of Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ lymphomas revealed detectable levels of p53 in most tumors (Figures 3c and d) .
We also wished to determine the stability of the p53R172P protein. These experiments were performed in vivo as standard culture conditions stabilize p53 whether it is mutant or wild type (Terzian et al., 2008) . Ionizing radiation was used to stimulate p53R172P stability. We therefore irradiated three wild-type and three p53 515C/515C mice with 5 Gy ionizing radiation and killed individual mice at 0, 2, 4 and 8 h time points (Figure 4) . At this dose, wild-type p53 was clearly stable at 4 h after irradiation, as was p53R172P. However, wild-type p53 levels had decreased by 8 h after irradiation, whereas p53R172P remained stabilized. These data indicate that the p53R172P levels are normally regulated, similar to wild-type p53, but in response to DNA damage (and likely oncogenic activation, for example, c-Myc expression) remained stable for a longer time.
p21 is activated in most Em-myc::p53 515C/ þ lymphomas As the majority (83%) of Em-myc::p53 515C/ þ and 100% of Em-myc::p53 515C/515C lymphomas retained a p53 515C allele and expressed detectable levels of p53, we next determined the levels of p21 in these lymphomas, as p53R172P is able to transactivate p21 but cannot transactivate p53-dependent apoptotic targets Liu et al., 2004; Barboza et al., 2006) . To this end, we analyzed p21 protein levels in Em-myc lymphomas using western blot analysis. Em-myc::p53
lymphomas expressed variable but detectable amounts of p21 (Figure 5a ). However, the levels of p21 were undetectable in Em-myc::p53 þ /-lymphomas as they had lost the wild-type p53 allele. High but variable amounts of p21 were also observed in most Em-myc::p53
and Em-myc::p53 515C/ þ lymphomas when compared with Em-myc::p53 þ /-lymphomas (Figures 5b and c) . Importantly, lymphomas from Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice, some of which retained only the p53 515C allele, also had high levels of p21 (Figure 5b ). Taken together, these data show that the Em-myc:: p53 515C/515C and Em-myc::p53 515C/ þ lymphomas retain the ability to activate p21 in vivo and suggest that the delay in the onset of Em-myc-dependent lymphoma observed in these mice may be dependent on p53R172P. , Em-myc::p53 515C/ þ and Em-myc::p53 þ /-lymphomas using a p53 antibody. (b) Lysates were prepared from splenic lymphomas of Em-myc::p53 þ / þ mice for western blotting analysis and p53 was detected using a p53 antibody. The numbers correspond to the animal number from which the tumors arose. b-actin serves as an internal loading control. Figure 4 p53R172P is stabilized in response to DNA damage. Wild type or p53 515C/515C mice, 6 weeks old, were untreated or treated with 5 Gy ionizing radiation. Spleens were harvested at 2, 4 or 8 h after treatment. Spleens from untreated (À) mice serve as a negative control. Lysates were prepared from the spleens for western blotting analysis and p53 was detected using a p53 antibody. The numbers correspond to the time, in hours, after treatment. b-actin serves as an internal loading control.
p53-dependent senescence delays lymphomagenesis SM Post et al p53R172P-dependent activation of cellular senescence in Em-myc-driven lymphomas As p53R172P is unable to activate p53-dependent apoptosis, yet Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice showed delayed lymphomagenesis, we next examined the net contribution of apoptosis for this delay. To this end, we examined lymphomas obtained from Em-myc::p53
, Em-myc::p53 þ / þ , Em-myc::p53 515C/ 515C and Em-myc::p53 515C/ þ mice. No statistically significant differences were observed in the levels of apoptosis in any of the lymphomas, regardless of p53 status (P ¼ 0.1; Figures 6a and b) , suggesting that apoptosis observed in each of these lymphomas is independent of p53. The observations that Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice survive longer ( Figure 1 ) and their lymphomas have higher p21 levels than Em-myc:: p53 þ /-lymphomas (Figures 5b and c) suggest that the increased survival of the Em-myc::p53 515C/515C and Em-myc:: p53 515C/ þ mice when compared with the Em-myc::p53
mice is a consequence of p53R172P-dependent activity.
To explore the mechanism of p53R172P-dependent increase in survival, lymphomas from Em-myc:: p53 515C/515C and Em-myc::p53 515C/ þ mice were tested for SA b-gal activity (Figure 7a ). Lymphomas from Em-myc:: p53 þ / þ , Em-myc::p53 515C/ þ and Em-myc::p53 515C/515C mice had 6.83 ± 1.90, 4.35 ± 1.13 and 5.10 ± 1.06% SA b-galpositive cells, respectively (Figure 7b) . Importantly, two of four lymphomas from Em-myc::p53 515C/ þ mice that were examined retained only the p53 515C allele, and showed increased SA-b-gal activity (4.76%) when compared with Em-myc::p53 þ /-lymphomas. Lymphomas from Em-myc:: p53 þ /-mice that had lost the wild-type p53 allele had few (0.74 ± 0.62%) SA b-gal-positive cells, indicating the p53-dependent nature of this phenotype (Figure 7b ). Altogether, these findings suggest that the delay in the onset of lymphoma in the Em-myc::p53
and Em-myc::p53 515C/ þ mice is at least partly due to the ability of the p53 515C allele to trigger a cellular senescence program. Last, we examined whether p53R172P affects lymphoma development before high-grade lymphoma formation. To this end, we killed mice at 4 to 5 weeks, before palpable tumor formation, and analyzed their spleens for apoptosis and senescence. Apoptosis was detected in all spleens, regardless of genotype (Supplementary Figure 1a) . Spleens from the Em-myc::p53
and Em-myc::p53 515C/ þ mice had slightly lower levels of apoptosis when compared with spleens from one Em-myc::p53 515C/515C mouse and three Em-myc::p53 þ /-mice. With regard to senescence, spleens from the Em-myc::p53 þ / þ and Em-myc::p53 515C/ þ were indistinguishable. Em-myc::p53 515C/515C spleens had an intermediate SA b-gal activity, whereas Em-myc::p53 þ /-mice had little activity (Supplementary Figure 1b) . As expected, these data suggest that the hypomorphic p53R12P protein is not as robust as wild-type p53 in initiating senescence.
Discussion
Despite conflicting reports, the prevailing paradigm contends that, although p53 regulates a plethora of processes that modulate cellular proliferation and survival, apoptosis is the most important (if not the only) function used by p53 for suppression of lymphomagenesis (Schmitt et al., 2002a) . To determine the specific contribution of p53-dependent cell-cycle arrest/ senescence functions on lymphomagenesis in vivo, we took advantage of a knock-in mouse model previously generated in our laboratory that expresses the p53R172P mutant protein. This mutant mouse model recapitulates the rare human p53 mutation that is unable to activate apoptotic genes but retains the ability to activate other p53-dependent activities such as cellcycle arrest Rowan et al., 1996) . þ /-and Em-myc::p53 þ / þ mice. Western blots of lysates isolated from Em-myc::p53 515C/ þ splenic lymphomas were performed and blotted with p21 and b-actin antibodies. The numbers correspond to the animal number from which the tumors arose. (b) p21 is expressed in the splenic lymphomas of Em-myc:: p53 515C/ þ mice. For Em-myc::p53 515C/ þ splenic lymphomas, the status of the p53 locus is indicated. B, both alleles retained; P, p53 515C allele retained; Wt, wild-type p53 allele retained. b-Actin serves as an internal loading control. (c) p21 is expressed in the splenic lymphomas of Em-myc::p53 515C/515C mice. g-tubulin serves as an internal loading control.
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Using this mouse, we previously showed that p53-dependent apoptosis was ablated in both the central nervous system and lymphatic tissues (Liu et al., 2004) . Furthermore, microarray expression analysis from p53 515C/515C mouse embryonic fibroblasts revealed the absence of p53-dependent apoptotic targets after treatment with ionizing radiation (Barboza et al., 2006) . In our study, no significant changes in apoptosis were observed in lymphomas, regardless of genotype. Altogether, these data indicate that p53R172P is functionally null for p53-dependent apoptotic activities. By taking advantage of this p53 mutant, we have now shown in vivo that p53-dependent activities, other than apoptosis, significantly extend the survival of Em-myc-expressing mice.
Both Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice showed significantly longer life spans than Em-myc::p53 þ /-mice. This observation, coupled with the fact that some B-cell lymphomas from Em-myc::p53 515C/ þ mice lose the p53 515C allele, indicates the functionality of p53R172P in inhibition of lymphomagenesis. It must be noted, however, that the Em-myc::p53 515C/ þ and Em-myc::p53 515C/515C
mice do ultimately succumb to lymphomas earlier than Em-myc::p53 þ / þ mice, reflecting the fact that the p53 515C allele is only partially functional. Interestingly, there was no statistical difference in the survival of Em-myc:: p53 515C/515C and Em-myc::p53 515C/ þ mice, regardless of the p53 status in the lymphomas. This may be due to several possibilities. First, in response to Em-myc expression, and Em-myc::p53 þ / þ mice. (a) Apoptosis was determined using hematoxylin and eosin (H & E) staining and immunohistochemistry using a cleaved caspase-3 antibody. (b) Apoptotic bodies were counted in Em-myc::p53 þ / þ , Em-myc::p53 515C/515C , Em-myc::p53 515C/ þ and Em-myc::p53 þ /-lymphomas from tumor-burdened mice. At least 300 cells were counted from three high magnification fields per tumor. (b) The mean and s.d. for each genotype were calculated from at least five lymphomas. Statistical significance was determined by a one-way analysis of variance (ANOVA) test.
p53-dependent senescence delays lymphomagenesis SM Post et al p53R172P may be dominant over wild-type p53. This possibility is supported by the observation that once stabilized, the p53R172P mutant remains stable for a longer time. Thus, it is plausible that having either one (Em-myc::p53 515C/ þ lymphomas that have lost the wildtype p53 allele) or two (Em-myc::p53
515C alleles may provide equivalent delays in lymphoma development, rendering their survival indistinguishable. Second, loss of one p53 allele may be a late event that dampens the effect on development of these tumors. This idea is supported by our observation that four healthy spleens from 4-week-old Em-myc::p53 515C/ þ mice still contained both p53 alleles, and expressed p53 and p21 (data not shown).
In Em-myc tumors, B cells overexpress c-myc, which in turn, activates p53, and likely the p53R172P protein, given what we know about mutant p53 stabilization (Figure 4 ; Terzian et al., 2008) ). Em-myc cells are thus under immense pressure to bypass the antiproliferative effects of p53, as shown by the fact that Em-myc::p53 þ /-cells circumvent p53 activity by almost universally deleting the wild-type allele (Eischen et al., 1999; Schmitt et al., 1999) . However, cells in the Em-myc:: p53 515C/515C mouse activate p53-dependent senescence without activating p53-dependent apoptosis. Therefore, it is conceivable that the selective pressure against the p53 515C allele in Em-myc::p53 515C/515C lymphoma cells is much more attenuated when compared with the negative selection pressure aimed at ablating a fully functional p53 gene. Nevertheless, the overall effect is a delay in the onset of lymphoma, suggesting that B-cell lymphomas in the Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ mice ultimately escape this senescence barrier. The Em-myc::p53 515C/515C and Em-myc::p53 515C/ þ in vivo data suggest several non-exclusive possibilities: (1) cells that have never entered senescence have a selective growth advantage and therefore can outgrow cells with an intact senescence response, (2) senescence may not be a dead-end event but rather a stopping point that can be bypassed if secondary mutations occur in the senescent cells, and (3) senescence may only slow the rate of lymphomagenesis, but it is unable to completely arrest tumor formation, which ultimately causes the mice to succumb to lymphomas.
The role of p21 in tumor suppression has been the subject of intense debate. Transfection of oncogenic Ras induces senescence in MEFs carrying wild-type p53, which results in low transformation potential (Serrano et al., 1997; Pantoja and Serrano, 1999) . This transformation potential is dependent on p53 and largely independent of p21. However, in vivo models using oncogenic Ras-infected keratinocytes showed that transformation potential was greatly increased in the absence of p21 (Missero et al., 1996) . In addition, using a similar model, a less robust but statistically significant p21-dependent effect on transformation potential was also observed (Weinberg et al., 1997) . In a murine p53-dependent senescence delays lymphomagenesis SM Post et al leukemia virus-infected model (mainly T-cell lymphoma), loss of p21 does not affect a tumor phenotype (Martins and Berns, 2002) . In addition, alterations of p21 are also rare in human cancers (Shiohara et al., 1994) . A critical point in the aforementioned studies is that p53 remains completely functional to initiate other p53-dependent pathways, including apoptotic pathways. MEFs derived from p53 515C/515C mice form fewer foci than MEFs derived from p53 À/À mice when infected with oncogenic Ras (Barboza et al., 2006) , suggesting that p53R172P also reduces transformation potential and induces senescence. Furthermore, deletion of p21 in p53 515C/515C mice results in increased tumor incidence (mostly T-cell lymphomas and sarcomas) when compared with p53 515C/515C mice (Barboza et al., 2006 ). In our model, Em-myc::p53 515C/515C lymphomas posses only the p53 515C allele, and hence show the ability to activate a p53R172P-dependent pathway. This results in increased survival and increased senescence when compared with the Em-myc::p53 þ /-lymphomas that lost their lone wild-type p53 allele. Collectively, these data confirm the important role of p53-dependent senescence in delaying Em-myc B-cell lymphomas. Although, the p53-dependent apoptotic pathway is clearly important in Em-myc B-cell lymphomas, the effect of senescence in delaying B-cell lymphoma development, and other tumors for that matter, must not be overlooked.
Materials and methods

Generation of mice
Generation of Em-myc, p53 515C/ þ and p53 þ /-mice has been previously described (Adams et al., 1985; Jacks et al., 1994a; Liu et al., 2004) . Em-myc::p53 515C/515C mice were generated by injecting 3-week-old Em-myc::p53 515C/ þ female mice with pregnant mare serum gonadatropin followed by injection of human chorionic gonadatropin 46 h later. These female mice were then mated with either p53 515C/ þ or p53 515C/515C males. Female mice were killed 18 h after introduction with the male mice and their oviducts were removed. Fertilized eggs at the one-cell stage were harvested and transplanted into pseudopregnant females. The background of Em-myc::
, Em-myc::p53 515C/ þ or Em-myc::p53 þ /-mice was 75% C57BL/6 and 25% 129Sv. All animal studies were performed according to the guidelines of the institutional animal care and use committee of MD Anderson, protocol number 079906634.
Histology and immunohistochemistry
Spleens, lymph nodes, thymuses and other tissues with gross tumor involvement were harvested from tumor-bearing mice and fixed in 10% phosphate-buffered formalin (Sigma, St Louis, MO, USA) followed by paraffin embedding. Serial sections were either stained with hematoxylin and eosin or subjected to immunohistochemistry. For immunohistochemistry, sections were deparaffinized and antigens were retrieved using citric acid and steam. It was performed using rabbit a-cleaved caspase-3 (Cell Signaling, Danvers, MA, USA), rat a-B220 (R&D Systems, Minneapolis, MN, USA) and rabbit a-p53 (CM5) (Vector Laboratories, Burlingame, CA, USA) and visualized using ABC and DAB kits from Vector Laboratories. Slides were counterstained with nuclear fast red.
Genotyping and lymphoma analysis Tails from Em-myc::p53 þ / þ , Em-myc::p53 515C/515C , Em-myc:: p53 515C/ þ or Em-myc::p53 þ /-mice were genotyped using primers previously described (Jacks et al., 1994b; Eischen et al., 1999; Liu et al., 2004) . Loss of heterozygosity at the p53 locus was determined by PCR amplification using primers 5 0 -TACTCTCCTCCCCTCAATAAGCTATTC-3 0 (exon 5) and 5 0 -GGATGGTGGTATACTCAGAGCC-3 0 (exon 7). The PCR reactions were separated using electrophoresis followed by DNA purification of the appropriate PCR products. Sequencing was performed using the exons 5 and 7 primers and analyzed using Chromas software. Fulllength p53 was analyzed for secondary mutations by first performing first-strand synthesis according to the manufacturer's protocol (Amersham, Buckinghamshire, UK) on total RNA isolated from lymphomas using the Qiagen RNeasy kit according to the manufacturer's protocol (Qiagen, Valencia, CA, USA). The resulting first-strand DNA was amplified by PCR using primers 5 0 -ATGGAGGAGTCACAGTCGGAT-3 0 (exon 2) and 5 0 -AGTCAGGCC CCACTTTCTTGAC-3 0 (exon 11). The PCR reactions were purified as above. Sequencing, using each of the aforementioned primers, was performed as above.
Immunoblotting analysis
Spleens, lymph nodes and thymuses were collected and frozen in liquid nitrogen. Protein extracts were prepared by passing the lymphomas through a series of needles in radioimmunoprecipitation assay buffer supplemented with complete protease and phosphatase inhibitors. Proteins were boiled in 2 Â sodium dodecyl sulfate sample buffer, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to polyvinylidene fluoride membranes (Amersham). Membranes were incubated with rabbit a-p53 (CM5) (Vector Laboratories), mouse a-p21 (BD Pharmingen, San Diego, CA, USA), rabbit a-g tubulin (Sigma) and mouse a-b-actin (Sigma) antibodies and antigen-antibody complexes were detected using enhanced chemiluminescence kit (Amersham) or BCIP/NBT Color Development Substrate (Promega, Madison, WI, USA).
Ionizing radiation
Healthy 6-week-old wild-type and p53 515C/515C mice were treated with 5 Gy ionizing radiation. Spleens were collected from the mice at 2, 4, or 8 h.
Senescence-associated b-galactosidase (SA b-gal) assay Lymph nodes were harvested and fixed in 4% paraformaldyhde for 2 h followed by overnight incubation in Hanks' balanced salt solution, without calcium and magnesium, supplemented with 10% sucrose (w/v) at 4 1C. The tissues were then incubated at room temperature for 6 h in 15% (w/v) sucrose/Hanks' balanced salt solution and then in 20% (w/v) sucrose/Hanks' balanced salt solution. Tissues were subsequently frozen in optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA) and 10 mm sections were mounted on slides. SA b-gal assays were then performed as described (Dimri et al., 1995) . Slides were counterstained with nuclear fast red.
Statistical analysis
Comparisons of mean values between the groups were analyzed using GraphPad Instat software (GraphPad Prism, GraphPad Software Inc., San Diego, CA). Statistical signifip53-dependent senescence delays lymphomagenesis SM Post et al cance of the differences was analyzed using unpaired Student's t-test for comparisons of two groups or by one-way analysis of variance for comparisons of more than two groups. Survival curves were plotted using the Kaplan-Meier method and compared by the log-rank (Mantel-Cox) test using GraphPad Prism. All P-values were two sided and the level of statistical significance was set at o0.05.
